Fatty liver inflammation study with liver biopsy
Part of Digestive system clinical trials.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with fatty liver disease (NAFLD) through imaging, and other causes of fatty liver (like certain medications, genetics, or heavy alcohol use) must be ruled out.
- You must have at least moderate liver scarring (fibrosis stage F2 or higher) based on a non-invasive test like FibroScan or a blood test.
- You must be at least 18 years old and willing to have a liver biopsy.
- You must not have advanced liver complications like cirrhosis with fluid buildup, bleeding, or confusion, and you must not have other liver diseases (such as hepatitis B or C, autoimmune hepatitis, or genetic hemochromatosis).
- You must not be pregnant, breastfeeding, or a prisoner, and you must not be under legal guardianship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study tracks how liver scarring (fibrosis) and fat buildup (steatosis) change over time in people with nonalcoholic fatty liver disease (NAFLD). It helps doctors understand risk factors so they can better predict and manage the disease.
This study looks at what drives non-alcoholic fatty liver disease and how it affects the body, including immune-related changes. You may be invited if you have confirmed fatty liver disease or, alternatively, if you are a healthy person with no liver disease.
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
This study collects health information from people with non-alcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver. It aims to learn more about the disease to improve future care.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.